The Nasdaq Biotech Index (NBI) rallied an impressive 5.95% on April 5th.  The conventional wisdom thrown around Wall Street was that the rally came after the U.S. Treasury passed a new set of rules to prevent any more U.S. drug companies from merging with foreign companies in order to pay… Read More

The Nasdaq Biotech Index (NBI) rallied an impressive 5.95% on April 5th.  The conventional wisdom thrown around Wall Street was that the rally came after the U.S. Treasury passed a new set of rules to prevent any more U.S. drug companies from merging with foreign companies in order to pay… Read More

This morning shares of Opko Health (OPK) fell hard in pre-market trading. The company received an FDA notice that it will not receive approval for its drug, Rayaldee.  What’s important here is that the denial was not directly related to Opko, but to the company that will manufacture the drug. … Read More

This morning shares of Opko Health (OPK) fell hard in pre-market trading. The company received an FDA notice that it will not receive approval for its drug, Rayaldee.  What’s important here is that the denial was not directly related to Opko, but to the company that will manufacture the drug. … Read More

We think the market is wrong about Opko Health (OPK). It’s acquisitions have already delivered profits and operating capital, buying it now could be an excellent long-term play. We are also looking to add this company to our EBIS list in the not too distant future.Opko’s strategy of consolidating its recent acquisitions resulted… Read More

We think the market is wrong about Opko Health (OPK). It’s acquisitions have already delivered profits and operating capital, buying it now could be an excellent long-term play. We are also looking to add this company to our EBIS list in the not too distant future.Opko’s strategy of consolidating its recent acquisitions resulted… Read More